Subspecialty

Intelligence in every question

Trusted by doctors in the largest health systems for learning, in-service and board exams.

subspecialty.com

Welcome back, Alice

Ophthalmology

Your Performance

Question Bank Progress

78% Complete2,221 of 2,847

Activity

SepOctNovDecJanSMTWTFS
156 Questions·89 Flashcards
Less
More

Focus Areas

Diabetic Retinopathy
Retina•45%
Primary Open-Angle
Glaucoma•52%
Smart Focus
Keratoconus
Cornea•38%
Smart Focus
Macular Degeneration
Retina•61%
Smart Focus

Recent Tests

100%50%0%
22%
45%
68%
75%
88%
T1T2T3T4T5

Flashcards

24reviews87%retention12due
New
45
Learning
23
Young
67
Mature
112
Total247
Again
8%
Hard
15%
Good
62%
Easy
15%
7d / 30d89% / 87%

Four ways we help you learn better

Expert-Reviewed Content

Thousands of board-style questions per specialty, aligned to official exam blueprints — with clinical images, detailed explanations, peer-reviewed by board-certified doctors for accuracy.

Clinical Image
Clinical Image
Clinical Image

Smart Tools

Our AI identifies your weak areas and builds personalized study materials from every mistake you make.

Smart Practice
Smart Focus
Smart Review
Smart Focus

Diabetic Retinopathy

Retina•12/28 attempted•43% accuracy
Core Concepts

• DR is classified into nonproliferative (NPDR) and proliferative (PDR) stages

• Microaneurysms are the earliest clinical sign appearing as small red dots

• Cotton wool spots indicate nerve fiber layer infarction

Where You're Struggling

• Distinguishing between moderate and severe NPDR using the 4-2-1 rule

• Understanding when to initiate anti-VEGF vs PRP for PDR

Consult

Ask questions while you study. Get instant answers.

Why is timolol contraindicated in asthma?
Timolol blocks β2 receptors, triggering bronchoconstriction.
Safer alternative?
Betaxolol—β1-selective, safer for asthma/COPD.
Glaucoma87%
POAG 92%Angle closure 88%NTG 71%
Retina74%
AMD 85%DR 68%RD 54%
Neuro-ophthalmology61%
Optic neuritis 72%Papilledema 58%CN palsies 49%

Track Your Mastery

See exactly where you stand across every subspecialty and topic — down to the concept level.

Learning in 3 steps

A simple, effective approach to learning.

Glaucoma

A 65-year-old presents with acute eye pain, nausea, and halos around lights. IOP is 54 mmHg with a mid-dilated pupil. What is the next step?

A.IV mannitol and topical timolol
72%
B.Laser peripheral iridotomy
18%
C.Topical pilocarpine alone
7%
D.Observe overnight
3%
1

Practice

Answer board-style questions with clinical images and detailed explanations.

Smart Practice

Targeted questions for weak areas

Smart Focus

Concise topic summaries

Smart Review

Personalized study documents

2

Learn

Adaptive learning reinforces weak spots with targeted questions and personalized study materials.

Board Exam Progress

On track

Performance Summary

Overall Accuracy
87%
Questions Completed2,847
Topics Mastered42 / 48
3

Succeed

Track your progress and ace your in-service and board exams.

Beyond static question banks.

Other Platforms

Static question banks

A 58-year-old patient with type 2 diabetes presents for routine eye examination. Fundoscopic exam reveals dot-blot hemorrhages and hard exudates. Which finding would indicate the need for immediate referral?

Correct! Neovascularization of the disc indicates proliferative diabetic retinopathy, requiring urgent referral.

Subspecialty
AI-powered adaptive learning
Glaucoma

A 65-year-old presents with acute eye pain and halos. IOP is 54 mmHg. Next step?

A.IV mannitol + timolol
72%
B.Laser iridotomy
18%
C.Topical pilocarpine
7%
D.Observe
3%
Your Answer:A
Correct Answer:A

Explanation

The correct answer is A. Acute angle-closure glaucoma is an emergency requiring immediate IOP reduction. IV mannitol provides rapid osmotic diuresis while topical timolol reduces aqueous production.

Answer B is incorrect. Laser iridotomy is definitive treatment but not first-line in acute attack—must lower IOP medically first.

Answer C is incorrect. Pilocarpine is ineffective when IOP >40-50 mmHg due to iris sphincter ischemia; use only after IOP lowered.

Answer D is incorrect. Never observe acute angle-closure—this is an ophthalmic emergency requiring immediate intervention.

Key Concept

Acute angle-closure = emergency → IV mannitol + timolol first → pilocarpine after IOP drops → laser PI definitive

Smart Focus

Acute Angle-Closure Glaucoma

Glaucoma•68% accuracy
Core Concepts

• Mid-dilated pupil is classic sign

• IOP reduction is first priority

• IV mannitol for rapid osmotic diuresis

• Topical timolol reduces aqueous production

• Pilocarpine after IOP lowered to open angle

Struggling With

• Timing of laser iridotomy vs medical tx

• Medical vs surgical management sequence

• When to use vs avoid pilocarpine

High-Yield Pearls

• Fellow eye prophylaxis—40-80% attack in 5 yrs

• Never dilate a shallow anterior chamber

• Laser PI is definitive, not medical therapy

Smart Review•Auto-generated

Acute Angle-Closure Glaucoma

Clinical Presentation

  • •Severe eye pain, headache, nausea/vomiting
  • •Mid-dilated, fixed pupil; corneal edema
  • •IOP typically > 40-50 mmHg

Diagnostic Approach

  • •Gonioscopy: closed or occludable angles
  • •AS-OCT for angle assessment

Management

  • •IV mannitol 1-2 g/kg + topical timolol
  • •Topical pilocarpine 1-2% after IOP lowered
  • •Laser peripheral iridotomy (definitive)

Prognosis

  • •Good if treated within 24-48 hours
  • •Risk of chronic glaucoma if delayed

Complications

  • •Permanent vision loss, optic nerve damage
  • •Fellow eye attack (40-80% within 5 years)

Real-time feedback

<250ms

Instant feedback

Get performance insights and personalized study material the moment you answer.

25%

Less Study Time*

AI-powered focus on your weak areas means less time reviewing what you already know.

3x

Faster Retention*

Retain missed concepts faster than re-doing questions or referencing textbooks.

*Data publication pending. Results based on internal testing.

More learning.
Less debt.

We charge less than everyone and give you more to learn from.

Frequently Asked Questions

Everything you need to know about Subspecialty.

We currently focus on ophthalmology with comprehensive subspecialty coverage. We are actively developing internal medicine, surgery, and pediatrics as future specialties.
We go beyond traditional question banks with AI-powered personalized learning. Our platform features a suite of AI-enabled tools for enhanced learning and adaptive flashcards for improved retention. Combined with board-certified physician-authored questions mapped to exam blueprints, we deliver a comprehensive, intelligent study experience that evolves with your performance—not just static content.
  • Basic tier gives you access to 100 questions in your selected specialty.
  • Pro tier offers unlimited questions, flashcards, Smart Review documents, exam simulation & timed modes, and Consult. We focus on providing the most essential features for effective board exam preparation.

Our AI-powered Smart features adapt to your learning:

  • Smart Practice — Creates targeted question sessions focused on your weak areas.
  • Smart Focus — Bite-sized topic summaries that break down core concepts you're struggling with.
  • Smart Review — Comprehensive study documents compiled from your missed questions for deeper review.
  • Consult — Your AI assistant that explains and clarifies concepts throughout the platform.

AI powers several parts of the platform:

  • Content Creation — We use large language models to help generate questions, explanations, and study content. Every piece is reviewed for clinical accuracy by board-certified physicians before publication.
  • Smart Practice — AI analyzes your performance to create targeted question sessions focused on your weak areas.
  • Smart Review — Builds personalized study materials from questions you miss.
  • Consult — An on-demand AI tutor that explains and clarifies concepts while you study.
  • Clinical Images — Any AI-generated images are clearly labeled alongside real clinical photographs.

Subspecialty

Product

  • Platform

Company

  • About
  • Changelog
  • Contact
  • Status

Legal

  • Privacy Policy
  • Terms of Service

© 2026 Subspecialty Inc. All rights reserved.